RAAS Inhibition and Cardiorenal Syndrome

Author(s): Macaulay Amechi C. Onuigbo

Journal Name: Current Hypertension Reviews

Volume 10 , Issue 2 , 2014

Become EABM
Become Reviewer


The consensus conference on cardio-renal syndromes (2008) defined ‘cardio-renal syndromes’ as ‘disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other’ and identified five subtypes of the syndromes. Various pathophysiologic mechanisms underlie cardiorenal syndrome including hemodynamic derangements, reduced cardiac output leading to impaired renal perfusion, reduced stroke volume, raised atrial filling pressures, elevated atrial pressures, sodium and water retention, venous congestion, right ventricular dysfunction and venous hypertension causing increased renal venous pressure, intra-abdominal hypertension, various neurohormonal adaptations including activation of the renin-angiotensin-aldosterone system, adaptive activation of the sympathetic nervous system, cytokine release and oxidative stress. Although there are standardized clinical guidelines for the management of heart failure, and chronic kidney disease, respectively, there are no similar consensus clinical guidelines for the management of the cardiorenal syndromes.

RAAS inhibition is advocated in treating systolic heart failure. There is evidence that RAAS inhibition is also useful in cardiorenal syndrome. However, RAAS inhibition, while potentially useful in the management of cardiorenal syndrome, is not the ‘magic bullet’, is sometimes limited by adverse renal events, is not applicable to all patients, and must be applied by physicians with due diligence and caution. Nevertheless, a more comprehensive multidisciplinary multipronged approach to managing patients with cardiorenal syndrome is even more pragmatic and commonsense given the multiple mechanisms and pathogenetic pathways implicated in the causation and perpetuation of cardiorenal syndrome.

Keywords: ACE inhibitor, angiotensin receptor blocker, cardiorenal syndrome, RAAS inhibition, unintended consequences.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [107 - 111]
Pages: 5
DOI: 10.2174/1573402111666141231144228
Price: $65

Article Metrics

PDF: 71